site stats

Olympia nct02032823

Web18. mar 2024. · 奥拉帕利此次适应证被批准是基于OlympiA（NCT02032823）研究，这是一项随机（1：1），双盲，安慰剂对照，涉及1836名gBRCAm HER2阴性高危早期乳腺癌患者的国际研究。. 研究的入组患者完成了确定性局部治疗和新辅助治疗或辅助化疗。. 患者被随机分配接受1年的奥拉帕 ...

Olaparib Improves Survival in BRCA+, High-Risk Early Breast Cancer

Web04. mar 2024. · The recommendations are based on data from the TAILORx (NCT00310180), RxPONDER (NCT01272037), SOFT (NCT00066690) and TEXT (NCT00066703), monarchE (NCT03155997), and OlympiA (NCT02032823) trials ... Web31. jan 2024. · OlympiA (NCT02032823) is a randomised, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy and safety of the PARP-inhibitor olaparib in patients … helsinki seurakunnat tapahtumat https://reneevaughn.com

Breast cancer drug, olaparib, depletes store EurekAlert!

Web12. mar 2024. · OlympiA (NCT02032823), un estudio internacional aleatorizado (1:1), doble ciego, controlado con placebo de 1836 pacientes con cáncer de mama temprano de alto riesgo gBRCAm HER2 negativo que completaron el tratamiento local definitivo y quimioterapia neoadyuvante o adyuvante, recibió la aprobación. Web在3期OlympiA试验（NCT02032823）中，与安慰剂相比，Lynparza辅助治疗显著延长了无侵袭性疾病生存期（IDFS）和总生存期（OS）。 乳腺癌是全球诊断最多的 ... Web07. apr 2024. · NICE considered evidence from AstraZeneca, the manufacturer of olaparib, in making their recommendation, namely, clinical trial evidence from the phase 3 OlympiA trial (NCT02032823). helsinki sentrum

Post-neoadjuvant treatment and the management of residual …

Category:OlympiA: A phase III, multicenter, randomized, placebo

Tags:Olympia nct02032823

Olympia nct02032823

ABCSG 41/ OlympiA: Adjuvantes Olaparib verbessert 3-Jahres …

Web01. maj 2015. · Abstract. Background A Phase II study showed that the PARP inhibitor olaparib (400 mg bid; capsules) exerts antitumor activity in BC pts with a gBRCAm (Tutt et al Lancet 2010). Three Phase III trials of olaparib monotherapy have been initiated in BC pts with a gBRCAm: OlympiA (NCT02032823), Neo-Olympia (D081EC00005), OlympiAD … Web04. jul 2024. · OlympiA (NCT02032823) es un estudio aleatorizado de fase III, doble ciego, en el que se inscribieron pacientes con mutación BRCA1/2 de línea germinal, cáncer de mama triple negativo, HER2 negativo, o cáncer de mama temprano de riesgo alto, con receptores hormonales positivos después del tratamiento primario local y de la …

Olympia nct02032823

Did you know?

Web케임브리지, 영국 -- 비즈니스와이어 -- 아스트라제네카(AstraZeneca)가 난소암 환자에 대해 백금기반 화학요법을 사용한 후 ‘린파자’(Lynparza)(성분명: 올라파립[olaparib])로 유지 치료하여 전체 생존기간(OS)이 연장된 것으로 나타난 Study 19임상시험의 3차 중간 분석 결과를 오늘 발표했다. 전체 생존기간 ... Web16. mar 2024. · OlympiA (NCT02032823) is a randomized, double-blind, parallel-group, placebo-controlled, multicenter, phase 3 study comparing olaparib to placebo in patients …

Web08. apr 2024. · More recently, the FDA also granted olaparib approval for adjuvant treatment of BRCA-mutated, HER2-negative high-risk early breast cancer, previously treated with chemotherapy in neoadjuvant or adjuvant scenarios, based on the OlympiA (NCT02032823) clinical trial . OlympiA was a phase III, double-blinded clinical trial with … Web10. jan 2014. · NCT02032823 Other Study ID Numbers: D081CC00006 NSABP B-55 ( Other Identifier: NSABP ) BIG 6-13 ( Other Identifier: Breast International Group ) First …

Web03. jun 2024. · Destacado como Late Breaking Abstract 1 no ASCO 2024, o estudo OlympiA mostrou que a adição de 1 ano do inibidor de PARP olaparibe após a conclusão do tratamento multimodal com quimioterapia (neo)adjuvante padrão, cirurgia e radioterapia, se indicada, melhorou significativamente a sobrevida livre de doença invasiva (IDFS) e a … Web14. jul 2016. · Bei der diesjährigen Tagung der AGO wurden zahlreiche Studien präsentiert, an denen österreichische Zentren aktiv beteiligt sind und deren Ergebnisse mit Spannung erwartet werden. Während die PARP-Inhibition beim BRCA-mutierten Ovarialkarzinom bereits erfolgreich etabliert wurde, muss ihre Effektivität beim Mammakarzinom erst …

Web18. jun 2024. · OlympiA研究纳入的患者在2014年就已开始入组，他们多是经过蒽环和紫杉类药物治疗后，再术后进行奥拉帕利一年辅助治疗。 然而在临床中，众所周知，经过新辅助治疗未能达到PCR的三阴性乳腺癌患者，其术后标准治疗实际上是采用卡培他滨进行强化治疗。

Web10. jun 2024. · Eine erste Zwischenanalyse der OlympiA-Studie zeigt eine signifikante Verbesserung des invasiven krankheitsfreien Überlebens bei Patientinnen mit HER2-negativem, BRCA1/2-Keimbahnmutiertem primärem Brustkrebs mit hohem Risiko nach 1 Jahr adjuvanter Behandlung mit dem PARP-Inhibitor Olaparib. helsinki seurakunta vaalikoneWeb18. mar 2024. · Approval was based on OlympiA (NCT02032823), a randomised (1:1), double-blind, placebo-controlled, international study of 1836 patients with germline … helsinki seurakuntaWeb23. mar 2024. · Adjuvant olaparib (Lynparza) induced a significant improvement in overall survival (OS) among previously treated patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer, according to findings of the OlympiA trial (NCT02032823) that were recently presented at the March 2024 ESMO Virtual Plenary.. … helsinki-seuraWeb10. jan 2014. · NCT02032823 Other Study ID Numbers: D081CC00006 NSABP B-55 ( Other Identifier: NSABP ) BIG 6-13 ( Other Identifier: Breast International Group ) First Posted: … helsinki shopWeb03. jun 2024. · (Funded by the National Cancer Institute and AstraZeneca; OlympiA ClinicalTrials.gov number, NCT02032823.) ... outside the United States. OlympiA is a … helsinki shoppailuWeb20. maj 2024. · Nachdem beim frühen Mammakarzinom die OlympiA-Studie ( [3]; NCT02032823) mit dem PARP-Inhibitor Olaparib ihren primären Endpunkt erreicht hat … helsinki shipyard uutisetWeb08. jun 2024. · Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, speaks on the findings of OlympiA (NCT02032823), a randomized, double-blind, Phase III trial evaluating adjuvant olaparib after neoadjuvant chemotherapy in patients with germline BRCA1/2 mutations (gBRCAm) and high-risk HER2-negative early breast cancer. … helsinki shad rapala